Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)

Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC r...

Full description

Autores:

Heredia, David
Barrón-Barrón, Feliciano
Cardona, Andrés Felipe
Campos, Saul T.
Rodríguez-Cid, Jerónimo Rafael
Martínez-Barrera, Luis Manuel
Alatorre, Jorge
Salinas, Miguel Ángel
Lara-Mejía, Luis
Flores-Estrada, Diana
Arrieta, Oscar

Tipo de recurso:

Article of journal

Fecha de publicación:

2021

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/5776

Acceso en línea:

http://hdl.handle.net/20.500.12495/5776
https://doi.org/10.2217/fon-2020-0747

Palabra clave:

Anaplastic lymphoma kinase
Brigatinib
Ceritinib
Crizotinib
Early access
Lung cancer
Non-small cell lung cancer
Real-world evidence

Rights

openAccess

License

Acceso abierto